The Competition Commission has initiated an early-stage investigation into several pharmaceutical manufacturers following a complaint from the national health department. The companies named include Ascendis, Pharma Q and Sonke, all of which supply medicines to the state.
Competition Commission spokesperson Siyabulela Makunga confirmed that a probe is underway. He would not elaborate on the allegations, saying only that the investigation is in its early stages. The Health Department also declined to comment, indicating the matter is now with the Commission.
Competition Pharma Probe Targets State Suppliers
While the details remain confidential, the Commission has clear powers in public procurement matters. It can investigate conduct associated with collusive tendering, including bid rotation, price fixing, and “cover pricing,” in which firms submit intentionally uncompetitive bids to create the appearance of competition.
The companies under scrutiny have strong links to the broader generics supply chain. Ascendis delisted from the JSE in 2025. India’s Micro Labs partly owns pharma Q. Sonke, a subsidiary of Indian generic manufacturer Sun Pharma. All three have supplied medicines to the public sector, placing them in the centre of a highly price-sensitive and strategically important market.
The Complaint fits a Wider Enforcement Push
This is not the first time the Health Department has referred concerns to competition authorities. In November 2025, the Commission announced it was investigating the South African subsidiary of Indian generic manufacturer Hetero for alleged collusion linked to a major HIV treatment tender. That tender was valued at about R15.5bn and was awarded in August 2025.
Recent public reporting has also highlighted rising pressure on medicine procurement systems, including supply continuity concerns in parts of the antiretroviral market. In January 2026, the Department of Health issued a public response after reports that two ARV tender suppliers had entered business rescue. That statement underscored the department’s focus on supply continuity and contract management.
Together, these developments suggest regulators are paying closer attention to both pricing integrity and resilience across state medicine contracts.
What the Competition Commission Pharma Probe Means for Procurement
For healthcare leaders, the key issue is what happens next. An early-stage investigation does not prove wrongdoing. However, it can lead to formal complaints, referrals to the Competition Tribunal, and potentially significant administrative penalties if prohibited conduct is established.
The news also appears to have caught the companies off guard. Ascendis said it was not aware of any Competition Commission investigation and could not respond to queries. Pharma Q’s managing director similarly stated that the company was unaware of the investigation.
In practical terms, this probe increases compliance risk for suppliers and raises governance expectations for bid teams, commercial executives, and boards. For the public sector, it sharpens the focus on tender design, detection tools, and supplier due diligence. For patients, the longer-term aim is a market that delivers reliable supply at fair, competitive prices.
Read the Original Article (May require a subscription)